No Clinically Significant Drug Interaction Between Tirzepatide and Veozah
Tirzepatide and Veozah (fezolinetant) can be safely used together without dose adjustments, as there is no documented pharmacokinetic or pharmacodynamic interaction between these medications.
Mechanism Analysis
Tirzepatide Metabolism and Interactions
Tirzepatide is a dual GIP/GLP-1 receptor agonist that undergoes minimal hepatic metabolism. As a peptide-based medication, it is primarily degraded by proteolytic enzymes rather than cytochrome P450 enzymes 1, 2. The drug exhibits:
- Minimal CYP-mediated metabolism
- No significant drug-metabolizing enzyme interactions
- Primary mechanism-of-action-mediated interactions limited to delayed gastric emptying 2
Veozah Metabolism and Contraindications
Veozah (fezolinetant) is an NK3 receptor antagonist that is primarily metabolized by CYP1A2, and to a lesser extent by CYP2C9 and CYP2C19 3. The FDA label explicitly states:
- Veozah is contraindicated with CYP1A2 inhibitors (weak, moderate, or strong) 3
- Tirzepatide is not a CYP1A2 inhibitor
Why These Medications Don't Interact
The key point is that tirzepatide does not inhibit or induce CYP1A2, which is the primary metabolic pathway for Veozah. Since tirzepatide:
- Is not metabolized by CYP enzymes to any clinically significant degree
- Does not inhibit CYP1A2 (Veozah's primary metabolic pathway)
- Does not affect drug transporters relevant to Veozah
- Has mechanism-of-action effects (delayed gastric emptying) that are clinically insignificant for most oral medications 2
Clinical Considerations
Gastric Emptying Effects
While tirzepatide delays gastric emptying, this has been shown to be clinically insignificant for most oral medications 2. The notable exceptions documented are:
- Oral contraceptives (with tirzepatide specifically)
- Levothyroxine (with oral semaglutide)
Veozah is not among the medications requiring special monitoring for gastric emptying effects.
Monitoring Recommendations
No specific monitoring is required when combining these medications beyond standard monitoring for each drug individually:
- For tirzepatide: Monitor for gastrointestinal side effects, weight loss, glycemic control (if diabetic), and signs of gallbladder disease 1, 4
- For Veozah: Monitor liver function tests as clinically indicated 3
Common Pitfalls to Avoid
- Do not confuse CYP substrate status with CYP inhibition: Veozah being a CYP1A2 substrate does not create an interaction with tirzepatide, which is neither a substrate nor inhibitor of this enzyme
- Do not unnecessarily delay either medication: There is no need to separate administration times or adjust doses
- Do not conflate GLP-1 RA class effects: While some oral medications may have altered absorption with GLP-1 RAs, this is medication-specific and not a class-wide contraindication
These medications can be prescribed together without restriction, dose adjustment, or special timing considerations 3, 2.